Emergent Biosolutions EBS Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.
The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Emergent Biosolutions's contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Emergent Biosolutions's contract liabilities?
- Emergent Biosolutions (EBS) reported contract liabilities of $17.6M in Q1 2026.
- How has Emergent Biosolutions's contract liabilities changed year-over-year?
- Emergent Biosolutions's contract liabilities increased by 97.8% year-over-year, from $8.9M to $17.6M.
- What is the long-term trend for Emergent Biosolutions's contract liabilities?
- Over 5 years (2020 to 2025), Emergent Biosolutions's contract liabilities has grown at a -23.6% compound annual growth rate (CAGR), from $55.5M to $14.4M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.